Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia
Vidya Perera(Bristol-Myers Squibb (Germany)), Andrew J. McLachlan(The University of Sydney), Thomas M. Polasek(Royal Adelaide Hospital), Annette S. Gross(Emory University), Gauri G. Rao(University of Southern California), Qin Yan(Southwest Medical University), Junzhe Xu(University at Buffalo, State University of New York), Alan Forrest(University of North Carolina at Chapel Hill)
Cited by 39
Related Papers
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k
Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis
|BMJ Open|2016|527
Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies
|Thrombosis and Haemostasis|2014|467
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib
|Clinical Pharmacokinetics|2000|424